Recently, the Class I innovative chemical drug Toludesvenlafaxine Hydrochloride Sustained-Release Tablets (Chinese trade name: 若欣林®) of Luye Pharma Group is approved for marketing by China NMPA. This drug is an innovative drug with independent intellectual property rights, of which the research and development is taken independently in China. It is indicated for the treatment of major depressive disorder.

　　The antidepressant effect of Toludesvenlafaxine Hydrochloride may be related to the enhancement of serotonin (5-HT) and norepinephrine (NE) effects in the central nervous system by inhibiting the reuptake of 5-HT and NE. This drug provides more treatment options available for patients with major depressive disorder.